Categories
Blood Cancer

Last Week in LA and Prepping for Flight Attendant Training ✈️ [Video]

Last week in LA, for a short while. Soooo excited to start flight attendant training so soon!love, kamkeep up with my journey here 🤠✰ ig: kam schalk✰ twitter: kamschalk✰ vsco: kammck✰ soundcloud: kammckA little bit about me:1. I am 23 years old!!2. I SURVIVED Stage 4 Hodgkin’s Lymphoma3. I am a college grad. omg getting old.Music:Music by Joey White – Trapped in the Marsh With You (Woman in the Dunes) – https://thmatc.co/?l=310056B6Music by Karrit Music – Lofi Sax Type Beat – https://thmatc.co/?l=7437EAB8Music by Frythm – Illusions – https://thmatc.co/?l=0C0CBBC5Music by Mr. Jello – Slow Down – https://thmatc.co/?l=C03A1870#hodgkinslymphoma​​​​ #cancersurvivor​​​​ #kamstrong

Categories
Blood Cancer

IMS session highlights: clinical challenges in multiple myeloma [Video]

Tiffany Richards, MS, ANP, AOCNP, MD Anderson Cancer Center, San Antonio, Texas, shares her highlights from the session on clinical challenges in multiple myeloma that was held at this year’s IMS meeting, commenting on the management of toxicities associated with immunotherapies, the importance of better diagnosing amyloidosis, and learning how to better use and sequence available immunotherapeutics. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

Efficacy of trametinib in patients with multiple myeloma with NRAS and KRAS mutations [Video]

Meral Beksac, MD, Ankara University, Ankara, Turkey, talks on the efficacy of trametinib in patients with triple-class refractory multiple myeloma who are KRAS or NRAS-mutated. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

Using feedback to improve the experience of patients with multiple myeloma in the UK [Video]

Monica Morris, MSc, RN, Myeloma UK, Edinburgh, UK, comments on the results of the Clinical Service Excellence Programme (CSEP), a best practice initiative aiming to help hospitals deliver optimal care to patients with multiple myeloma. In this program, patients were asked to fill in a patient experience questionnaire. Overall, it showed that patients were struggling with waiting time and would like to have clear communication with their clinicians, as well as good coordination between different specialists. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

Immune reconstitution and vaccination in multiple myeloma [Video]

Mattia D’Agostino, MD, University of Turin, European Myeloma Network, Turin, Italy, shares the key topics that were discussed at the session on immune reconstitution and vaccination in multiple myeloma that was held at this year’s IMS meeting. In this session, experts discussed anti-infectious and anti-tumor immunity and predictors of response to COVID-19 and other anti-infectious vaccines. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

Using MRD to guide therapy in multiple myeloma [Video]

Mattia D’Agostino, MD, University of Turin, European Myeloma Network, Turin, Italy, comments on how measurable residual disease (MRD) can be used to guide therapy in multiple myeloma. Dr D’Agostino explains that patients who are MRD-positive after treatment may benefit from changing therapy in order to achieve MRD negativity whereas MRD-negative patients may benefit from treatment de-escalation. However, this tool is not yet available in clinical practice. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

Treatment options for patients with Hodgkin lymphoma who progress after brentuximab vedotin [Video]

Alex Herrera, MD, City of Hope, Duarte, CA, discusses treatment options for patients with Hodgkin lymphoma (HL) who progress after brentuximab vedotin or PD1 blockade, including epigenetic modifying agents, antibody drug conjugates (ADCs) such as camidanlumab tesirine, and other cellular therapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

When Myeloma Comes Back – M-Power New York [Video]

When Myeloma Comes Back Dr. Saad UsmaniMemorial Sloan Kettering Cancer CenterM-Power Community WorkshopOctober 1, 2022Download slides here: https://m-powernewyork.myeloma.org/_______________Improving Lives | Finding the CureFounded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.Subscribe to our channel: https://www.youtube.com/c/IMFMyelomaVisit our website at: https://www.myeloma.orgFind us online:Facebook: @myeloma | https://facebook.com/myelomaTwitter: @IMFMyeloma | https://twitter.com/IMFmyelomaInstagram: @imfmyeloma | https://www.instagram.com/imfmyelomaLinkedIn: https://www.linkedin.com/company/international-myeloma-foundationSupport the IMF! http://bit.ly/WskQHCCategoryNonprofits & ActivismLicenseStandard YouTube LicenseIn most cases, captions are autogenerated by YouTube.

Categories
Blood Cancer

I Had No Symptoms When I Was Diagnosed With a Terminal Cancer | Cherylinn’s Story [Video]

After a freak accident sent Cherylinn N. to the hospital, she was told to see a primary care doctor. She went to the doctor, even though she wasn’t experiencing any symptoms, and was then diagnosed with stage 4 mantle cell lymphoma (MCL) and was told it was terminal. That was in 2005. In this story, she talks about how she made the choice to fight and how she remained positive through chemotherapy and relapses. Full story & transcript → https://www.thepatientstory.com/cancers/non-hodgkin-lymphoma/mantle-cell-lymphoma-mcl/cherylinn-n/Join Our Community for access to our full-length conversation at https://www.thepatientstory.com/join.After you’ve registered, click in the upper right hand “FORUM,” and you will be able to see our members-only content.Join Our Community:Website : https://www.thepatientstory.com/Facebook: @ThePatientStoryInstagram: @ThePatientStoryTwitter: @patient_story______________________________Contents of this video:00:00 – Intro01:51 – How did you find out you had cancer?06:24 – How did you break the news to your children?07:55 – When did you find out it was mantle cell lymphoma?10:21 – What were the side effects from the R-CHOP?13:41 – Going into remission15:06 – Relapse and treatment18:26 – Choosing treatment options23:35 – Remaining positive through relapse______________________________#MantleCellLymphoma #Lymphoma #mcl #diagnosis #bloodcancer #terminal #stage4cancer #positivity #Nonhodgkinlymphoma #NHL #cancerstories #cancerpatient #cancersurvivor #patientstories #thepatientstory